AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01440816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.
Study NCT01440816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Study NCT03776201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
Study NCT02396563 — intervention group
Intervention type: PROCEDURE
Intervention: epidural analgesia
Study NCT02396563 — intervention group
Intervention type: DRUG
Intervention: Ropivacaine
Study NCT01770236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
Study NCT02858947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aelite Flo
Description: Microhybrid flowable composite
Study NCT02858947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: x-tra base
Description: Bulk-fill flowable composite
Study NCT01331980 — intervention group
Intervention type: DEVICE
Intervention: Peripheral quantitative computed tomography (pQCT)
Description: A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
Study NCT01331980 — intervention group
Intervention type: DEVICE
Intervention: Dual X-ray absorptiometry (DXA)
Description: A total body DXA scan will be conducted at a single study visit
Study NCT00609570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NanoGreens
Description: fruits and vegetables
Study NCT00609570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Whey
Study NCT00609570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium pills
Description: CA
Study NCT03944408 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: stent implantation
Description: stent implantation
Study NCT03944408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent implantation
Description: stent implantation
Study NCT01351116 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBR plus HDRIB
Description: EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
Study NCT02647931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy for Muscle Tension Dysphagia
Description: Voice therapy for Muscle Tension Dysphagia
Study NCT03391258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Regeneration with GLAM technique
Description: Bone regeneration with GLAM technique in full arch implant supported rehabilitation
Study NCT03947333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care
Description: The My Diabetes Care is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
Study NCT02702076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Description: Continuous subcutaneous infusion of apomorphine during waking day
Study NCT01350128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide HFA Inhalation Aerosol
Description: Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
Study NCT01350128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Matching placebo to PT001 MDI administered as two puffs BID for 7 days
Study NCT01283126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: euglycemic and hypoglycemic clamp
Description: Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
Study NCT00779103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Histrelin Subcutaneous Implant
Description: histrelin subcutaneous 50 mg implant
Study NCT02559869 — intervention group
Intervention type: DRUG
Intervention: [18F] GE-180
Description: PET Tracer Ligand
Study NCT02692859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine
Description: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
Study NCT01552239 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT/IGRT, Tumor resection, Brachytherapy
Description: All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection
Study NCT04033159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DYN101
Description: DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
Study NCT01841593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Isentress 400mg tablet taken twice daily
Study NCT02909556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: Transcatheter aortic valve replacement via transfemoral access
Study NCT02290288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal surgery
Study NCT02290288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic surgery
Study NCT02020005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored 2mg nicotine gum
Study NCT02020005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored 4mg nicotine gum
Study NCT02020005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-flavored 2mg nicotine gum
Study NCT02020005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-flavored 4mg nicotine gum
Study NCT02020005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-flavored nicotine inhaler
Study NCT02020005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mint-flavored nicotine ihaler
Study NCT02702076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous subcutaneous infusion of placebo during waking day
Study NCT01873274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MK-7 containing capsule
Study NCT01873274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: basic yogurt enriched with MK-7
Study NCT01873274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrient-enriched yogurt with MK-7
Study NCT03520361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Description: Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
Study NCT03466476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Consensus TracPatch
Description: Consensus TracPatch will be attached to the participant's shin approximately two inches below the knee through use of an adhesive strip similar to a standard bandage for 6 weeks after total knee arthroplasty.
Study NCT00218673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Description: groups sessions, 8
Study NCT02882555 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
Study NCT02882555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity \<10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
Study NCT02882555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study NCT03520361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L PEG/Asc
Description: Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
Study NCT00761891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewable aspirin
Description: chewable aspirin 81mg daily for 2 weeks
Study NCT02882555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study NCT02882555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study NCT02882555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study NCT02103894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807 ([18F]MNI-777)
Description: All enrolled subjects will undergo an \[18F\]MNI-777 PET imaging visit. For individuals with AD or CTE, \[18F\]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by \[18F\]florbetapir imaging) and tau protein uptake (measured by \[18F\]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, \[123I\]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
Study NCT00449956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride (+) timolol maleate
Description: Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
Study NCT00449956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: timolol maleate
Description: timolol maleate 0.5%, 8-week
Study NCT00449956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: dorzolamide hydrochloride
Description: dorzolamide hydrochloride 1%, 8-week
Study NCT00046735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
Study NCT00892567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 Peptides from Her-2/neu, CEA, & CTA
Description: Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
Study NCT01253252 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F] Fluorodeoxyglucose PET Scan Imaging
Description: Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations.
Study NCT01253252 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
Study NCT01253252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling for biological investigations
Description: A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
Study NCT02786485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rivogenlecleucel
Description: T cells transduced with iCasp safety switch
Study NCT02786485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: administered to treat GVHD
Study NCT04637958 — intervention group
Intervention type: DEVICE
Intervention: THA
Description: Total hip arthroplasty
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylometazoline - intranasal application
Description: Applied as needed up to 5 consecutive days when prominent congestion
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Xylometazoline - intranasal application
Description: Applied as needed up to 5 consecutive days when prominent congestion
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xylometazoline - intranasal application
Description: Applied as needed up to 5 consecutive days when prominent congestion
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine - intranasal application
Description: Applied as needed when prominent symptom is rhinorrhea
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Azelastine - intranasal application
Description: Applied as needed when prominent symptom is rhinorrhea
Study NCT01841593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azelastine - intranasal application
Description: Applied as needed when prominent symptom is rhinorrhea
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate - intranasal application
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mometasone furoate - intranasal application
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate - intranasal application
Description: Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyl-propyl-methyl cellulose powder - intranasal application
Description: Applied intranasally immediately after every application other intranasal formulation
Study NCT02557269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Lactose powder
Description: Applied intranasally immediately after every application other intranasal formulation
Study NCT02291861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-809
Description: SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine 20 mg
Description: 1 tablet per os - as needed
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bilastine 20 mg
Description: 1 tablet per os - as needed
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bilastine 20 mg
Description: 1 tablet per os - as needed
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 5 mg
Description: Per os - if needed (only in case of broncial obstruction)
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone 5 mg
Description: Per os - if needed (only in case of broncial obstruction)
Study NCT02557269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone 5 mg
Description: Per os - if needed (only in case of broncial obstruction)
Study NCT02291861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
Study NCT03663049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinue statin
Description: Discontinue statin as prescribed for 12 weeks
Study NCT04400773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Types of exercises include resistance tubing 90-90 external rotation, plyometric push-up, reverse overhead throws, rotational wall throw, overhead medicine ball, chest passes.
Study NCT04400773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training exercises
Description: Types of exercise include push-ups, resisted external rotation, overhead presses, biceps curl, bench presses and triceps kick backs.
Study NCT00223990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A
Description: FMP1/AS02A candidate malaria vaccine
Study NCT00223990 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RabAvert
Description: RabAvert rabies vaccine
Study NCT00267202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
Study NCT00267202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
Study NCT00267202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunotherapy
Description: Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours.